Merrion Pharmaceuticals, Inc. is Issued a Key U.S. Patent for Orazol(TM), Their Lead Product to Treat Bone Metastases Associated With Prostate, Breast and Other Cancers

DUBLIN, Ireland, May 7, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals plc (IEX:MERR), a pharmaceutical development company, today announces that it has been granted a further U.S. Patent, increasing the protection for their lead product, Orazol™.